Procept Biorobotics Corp. (PRCT)
NASDAQ:PRCT
Want to see PRCT full AI Analyst Report?
Top Page
PROCEPT BioRobotics
(NASDAQ:PRCT)
Select Model
Select Model
Rating:48Neutral
Price Target:
$27.00
▲(7.40% Upside)
Action:Reiterated
Date:05/01/26
The score is held back primarily by ongoing losses and persistent negative free cash flow despite strong revenue growth and improving gross margins. Technicals also remain weak with the stock below key moving averages and negative MACD. Offsetting these, the earnings call was constructive with reaffirmed high-growth guidance and an explicit path toward positive adjusted EBITDA by Q4, though near-term execution and cost pressures remain key risks.
Positive Factors
Revenue & Procedure Growth
Management's reiterated FY2026 revenue and procedure targets (27–33% revenue growth; 60k–64k U.S. procedures) signal durable commercial adoption. Consistent procedure volume growth underpins repeatable equipment placements and recurring consumable demand, supporting multi‑period top‑line expansion.
Negative Factors
Negative Cash Flow
Persistent negative operating and free cash flows mean the business remains reliant on external financing or available liquidity to fund growth. Although burn has improved versus prior years, sustained outflows limit financial flexibility and increase refinancing or dilution risk if revenue ramps slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Procedure Growth
Management's reiterated FY2026 revenue and procedure targets (27–33% revenue growth; 60k–64k U.S. procedures) signal durable commercial adoption. Consistent procedure volume growth underpins repeatable equipment placements and recurring consumable demand, supporting multi‑period top‑line expansion.
Read all positive factors
PROCEPT BioRobotics Key Performance Indicators (KPIs)
Any
Revenue by Segment
Separates income from capital device sales, consumable disposables, and recurring services or training, showing how much revenue is one-time versus repeatable. A higher share of consumables and service revenue points to more predictable, annuity-like cash flow from the installed base, while heavy reliance on device sales makes results more dependent on hospital budgets and adoption cycles.
Separates income from capital device sales, consumable disposables, and recurring services or training, showing how much revenue is one-time versus repeatable. A higher share of consumables and service revenue points to more predictable, annuity-like cash flow from the installed base, while heavy reliance on device sales makes results more dependent on hospital budgets and adoption cycles.
Data provided by:
The Fly
The FlyPROCEPT BioRobotics (PRCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.55B
Dividend YieldN/A
Average Volume (3M)1.51M
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth29.26%
EPS Growth-7.59%
CountryUS
Employees756
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.82
Shares Outstanding56,918,842
10 Day Avg. Volume1,413,482
30 Day Avg. Volume1,511,368
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue4.05
Enterprise Value/Gross Profit6.43
Enterprise Value/Ebitda-12.74
Forecast
1Y Price Target
$33.14Price Target Upside31.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.53
Revenue Forecast (FY)$398.94M
PROCEPT BioRobotics Business Overview & Revenue Model
Company Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urolog...
How the Company Makes Money
PROCEPT BioRobotics primarily makes money by selling and placing its AQUABEAM Robotic System into hospitals and surgical centers and then generating recurring revenue from the installed base through procedure-related disposable and consumable prod...
PROCEPT BioRobotics Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive operational and commercial trajectory: robust top‑line growth (20% revenue; ~30% procedure growth), margin expansion to management targets (65% gross margin), pricing discipline and meaningful clinical/regulatory wins (EAU guideline upgrade, FDA clearance). These positives are balanced against higher operating expenses, larger GAAP and adjusted EBITDA losses in Q1, tariff headwinds and short‑term disruption from a commercial realignment that push some benefits into the back half of 2026. Management reaffirmed full‑year guidance while taking a prudent near‑term stance, expecting improved leverage and positive EBITDA in Q4.Positive Updates
Revenue Growth
Total revenue of $83.1 million in Q1 2026, representing 20% year‑over‑year growth and setting a strong start to the year.
Negative Updates
GAAP Losses and EBITDA Pressure
Net loss of $31.6 million in Q1 2026 compared to $24.7 million in Q1 2025; adjusted EBITDA loss of $18.1 million vs a loss of $15.8 million a year ago — indicating larger absolute losses despite revenue growth.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue of $83.1 million in Q1 2026, representing 20% year‑over‑year growth and setting a strong start to the year.
Read all positive updates
Company Guidance
Management reiterated full-year 2026 guidance of total revenue of approximately $390–$410 million (growth ~27–33% vs. 2025), including international revenue of $50–$51 million, total U.S. procedures of 60,000–64,000 (growth ~39–48%), and a full-year gross margin of ~65% (which assumes $5–$6M of tariff expense vs. $1.3M in FY2025 and excludes potential tariff-refund upside). They now expect new U.S. system pricing of $450,000–$460,000 for the remainder of the year (implying a full-year system ASP toward ~$460,000), a full-year adjusted EBITDA loss of $30M to $17M with positive adjusted EBITDA in Q4 at both ends of the revenue range, and Q2 revenue of $91–$95M (growth ~15–20%); management also reiterated a ~1:1 handpiece-to-procedure ratio for the year with handpiece ASP ≈ $3,500. For context, Q1 results that inform the guide included revenue of $83.1M (20% YoY), U.S. revenue $72M (19% YoY), ~12,200 U.S. procedures (≈30% YoY), 49 Hydros systems sold (ASP ≈ $485,000), U.S. handpiece/consumable revenue $43M, Q1 gross margin 65%, adjusted EBITDA loss $18.1M, net loss $31.6M, and cash/reserves of $249M as of March 31, 2026.PROCEPT BioRobotics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
66
Positive
Cash Flow
37
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.02M | 308.05M | 224.50M | 136.19M | 75.01M | 34.47M |
| Gross Profit | 202.81M | 196.23M | 137.10M | 71.05M | 37.09M | 15.87M |
| EBITDA | -102.38M | -97.47M | -82.00M | -98.09M | -79.13M | -50.72M |
| Net Income | -102.47M | -95.57M | -91.41M | -105.90M | -87.15M | -59.85M |
Balance Sheet | ||||||
| Total Assets | 487.06M | 508.08M | 534.02M | 404.72M | 309.33M | 337.02M |
| Cash, Cash Equivalents and Short-Term Investments | 245.64M | 286.50M | 333.73M | 257.22M | 222.64M | 304.32M |
| Total Debt | 51.66M | 51.62M | 80.25M | 79.20M | 77.32M | 54.10M |
| Total Liabilities | 139.40M | 142.21M | 131.80M | 123.97M | 112.26M | 69.93M |
| Stockholders Equity | 347.67M | 365.87M | 402.22M | 280.75M | 197.07M | 267.09M |
Cash Flow | ||||||
| Free Cash Flow | -80.57M | -58.34M | -103.62M | -133.21M | -83.03M | -57.93M |
| Operating Cash Flow | -70.13M | -48.98M | -99.21M | -108.00M | -80.38M | -57.33M |
| Investing Cash Flow | -10.43M | -9.36M | -4.41M | -25.21M | -2.65M | -592.00K |
| Financing Cash Flow | 10.12M | 11.19M | 180.13M | 167.79M | 3.61M | 262.12M |
PROCEPT BioRobotics Technical Analysis
Negative
25.14
Price Trends
25.34
Positive
26.92
Negative
31.01
Negative
Market Momentum
0.59
Positive
50.29
Neutral
38.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRCT, the sentiment is Negative. The current price of 25.14 is below the 20-day moving average (MA) of 26.45, below the 50-day MA of 25.34, and below the 200-day MA of 31.01, indicating a neutral trend. The MACD of 0.59 indicates Positive momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 38.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRCT.
PROCEPT BioRobotics Risk Analysis
PROCEPT BioRobotics disclosed 77 risk factors in its most recent earnings report. PROCEPT BioRobotics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PROCEPT BioRobotics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $4.05B | 37.68 | 9.13% | ― | 12.40% | ― | |
61 Neutral | $1.19B | 9.05 | 17.98% | ― | 8.94% | 102.92% | |
54 Neutral | $1.08B | 91.25 | 2.66% | ― | 17.59% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.19B | -9.52 | -443.09% | ― | 22.55% | 27.87% | |
48 Neutral | $1.55B | ― | -27.70% | ― | 29.26% | -7.59% | |
44 Neutral | $788.52M | -77.01 | -23.00% | ― | 119.23% | 40.14% |
* Healthcare Sector Average
PRCT
PROCEPT BioRobotics
26.33
-31.61
-54.56%
ATEC
Alphatec Holdings
7.75
-4.55
-36.99%
AORT
Artivion
22.19
-6.52
-22.71%
LIVN
LivaNova
73.80
30.39
70.01%
INSP
Inspire Medical Systems
41.36
-92.37
-69.07%
SSII
SS Innovations International
3.94
-2.05
-34.22%
PROCEPT BioRobotics Corporate Events
Business Operations and StrategyExecutive/Board Changes
PROCEPT BioRobotics Adds Independent Director to Audit Committee
Positive
Mar 6, 2026
On March 5, 2026, PROCEPT BioRobotics expanded its board of directors from eight to nine members and appointed former Shockwave Medical Chief Financial Officer Daniel Puckett as a Class III director, with his term running until the 2027 annual mee...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.